We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Move paves the way for implementation of cross-border ETF link between the two countries
Link will allow providers to sell products directly to investors in the other market
SK Bioscience’s $1.3bn IPO comes after group signed deal to make jabs for AstraZeneca
Change in Kospi 200 composition prompts US venues to suspend related derivatives
Biologics listing expected to raise Won2tn-Won3tn as parent group’s main growth driver
Lure of higher stock prices and relaxed rules tempt companies to market
Move could boost market capitalisation by stoking appetite among smaller investors
International Edition
